featured
Outcomes After Switching Eyes That Were Stable on Aflibercept to Ranibizumab vs Continuing Aflibercept in Patients With Neovascular AMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Graefe's Archive for Clinical and Experimental Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration
Graefes Arch. Clin. Exp. Ophthalmol 2022 Aug 01;260(8)2509-2516, M Salabati, A Obeid, R Mahmoudzadeh, O Gupta, A Chiang, M Spirn, MA Klufas, J HsuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.